Loading
2 standard-of-care settings across 1 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.
| Line | All comers |
|---|---|
| Other settings | 2 |
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Typical lesion | Topical fluorouracil or imiquimod, cryotherapy, curettage and cautery, photodynamic therapy, surgical excision, Mohs surgery, radiotherapy or laser; Cancer Research UK states that all of these can work well and that cure rates are high. The choice is driven by the site, the size, how well the skin there heals and what the person can manage at home. The treatment layer of this family carries the detail. | British Association of Dermatologists guidelines for the management of people with cutaneous squamous cell carcinoma in situ (Bowen disease) 2022 | 86 | |
| All comers | If invasion is found | The diagnosis becomes invasive cutaneous squamous cell carcinoma and is managed on that pathway, with the adjacent Bowen's disease itself usually counted as a high-risk feature of the invasive tumour (RCPath G124). See the cutaneous squamous cell carcinoma page. | - |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.